BR112022016015A2 - Composição farmacêutica líquida, nebulizador e método de tratamento ou prevenção de doença - Google Patents

Composição farmacêutica líquida, nebulizador e método de tratamento ou prevenção de doença

Info

Publication number
BR112022016015A2
BR112022016015A2 BR112022016015A BR112022016015A BR112022016015A2 BR 112022016015 A2 BR112022016015 A2 BR 112022016015A2 BR 112022016015 A BR112022016015 A BR 112022016015A BR 112022016015 A BR112022016015 A BR 112022016015A BR 112022016015 A2 BR112022016015 A2 BR 112022016015A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
nebulizer
disease
prevention
Prior art date
Application number
BR112022016015A
Other languages
English (en)
Inventor
Lionel Spargo Peter
Andrew Haywood Phillip
James French Edward
Original Assignee
Verona Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Plc filed Critical Verona Pharma Plc
Publication of BR112022016015A2 publication Critical patent/BR112022016015A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA LÍQUIDA, NEBULIZADOR E MÉTODO DE TRATAMENTO OU PREVENÇÃO DE DOENÇA. A presente invenção refere-se a uma composição farmacêutica líquida apropriada para administração por meio de inalação, que compreende: (i) partículas de ensifentrina; (ii) glicopirrolato; e (iii) diluente, em que o diluente compreende água, em que: o glicopirrolato é dissolvido no diluente; a concentração de glicopirrolato é menor ou igual a 5,0 mg/ml; e o pH da composição farmacêutica líquida é de 3,0 a 6,0. A presente invenção também se refere a um nebulizador que compreende a composição farmacêutica líquida.
BR112022016015A 2020-02-27 2021-02-26 Composição farmacêutica líquida, nebulizador e método de tratamento ou prevenção de doença BR112022016015A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2002786.8A GB202002786D0 (en) 2020-02-27 2020-02-27 Liquid pharmaceutical composition
PCT/GB2021/050496 WO2021171034A1 (en) 2020-02-27 2021-02-26 Liquid pharmaceutical composition comprising ensifentrine and glycopyrrolate

Publications (1)

Publication Number Publication Date
BR112022016015A2 true BR112022016015A2 (pt) 2022-10-11

Family

ID=70278709

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022016015A BR112022016015A2 (pt) 2020-02-27 2021-02-26 Composição farmacêutica líquida, nebulizador e método de tratamento ou prevenção de doença

Country Status (24)

Country Link
US (1) US20230112220A1 (pt)
EP (2) EP4110292B1 (pt)
JP (1) JP2023516630A (pt)
KR (1) KR20220149669A (pt)
CN (1) CN115279343A (pt)
AU (1) AU2021227456A1 (pt)
BR (1) BR112022016015A2 (pt)
CA (1) CA3166952A1 (pt)
DK (1) DK4110292T3 (pt)
ES (1) ES2970571T3 (pt)
FI (1) FI4110292T3 (pt)
GB (1) GB202002786D0 (pt)
HR (1) HRP20240288T1 (pt)
HU (1) HUE065531T2 (pt)
IL (1) IL295442A (pt)
LT (1) LT4110292T (pt)
MX (1) MX2022010014A (pt)
PL (1) PL4110292T3 (pt)
PT (1) PT4110292T (pt)
RS (1) RS65330B1 (pt)
SI (1) SI4110292T1 (pt)
SM (1) SMT202400076T1 (pt)
WO (1) WO2021171034A1 (pt)
ZA (1) ZA202208763B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688191C2 (ru) 2014-05-12 2019-05-21 ВЕРОНА ФАРМА ПиэЛСи Новое лечение
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4685243B2 (ja) 1999-03-31 2011-05-18 ベローナ・ファーマ・ピーエルシー ピリミド［６，１−ａ］イソキノリン−４−オン誘導体
NZ587561A (en) * 2008-02-26 2012-10-26 Elevation Pharmaceuticals Inc Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations (an muscarinic antagnoist)
JP6560986B2 (ja) * 2013-03-15 2019-08-14 ヴェローナ ファーマ ピーエルシー 複合製剤
CN106794157B (zh) * 2014-09-15 2021-03-09 维罗纳制药公司 包含rpl554的液体吸入制剂

Also Published As

Publication number Publication date
RS65330B1 (sr) 2024-04-30
ZA202208763B (en) 2024-01-31
HRP20240288T1 (hr) 2024-05-24
CN115279343A (zh) 2022-11-01
HUE065531T2 (hu) 2024-05-28
PL4110292T3 (pl) 2024-05-20
FI4110292T3 (fi) 2024-03-01
EP4110292B1 (en) 2024-01-10
PT4110292T (pt) 2024-01-31
MX2022010014A (es) 2022-10-18
LT4110292T (lt) 2024-02-12
WO2021171034A1 (en) 2021-09-02
EP4110292A1 (en) 2023-01-04
CA3166952A1 (en) 2021-09-02
IL295442A (en) 2022-10-01
SMT202400076T1 (it) 2024-03-13
EP4306129A3 (en) 2024-04-17
ES2970571T3 (es) 2024-05-29
EP4306129A2 (en) 2024-01-17
JP2023516630A (ja) 2023-04-20
AU2021227456A1 (en) 2022-09-08
US20230112220A1 (en) 2023-04-13
KR20220149669A (ko) 2022-11-08
SI4110292T1 (sl) 2024-03-29
DK4110292T3 (da) 2024-02-19
GB202002786D0 (en) 2020-04-15

Similar Documents

Publication Publication Date Title
BR112022016015A2 (pt) Composição farmacêutica líquida, nebulizador e método de tratamento ou prevenção de doença
BR112022019557A2 (pt) Inibidores de replicação de norovírus e coronavírus
TNSN08445A1 (fr) Derives de triazolopyrazine utiles comme agent anticancereux
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
EA201200490A1 (ru) Стабильный совместный состав, содержащий хиалуронидазу и иммуноглобулин, и способы его применения
EA200602191A1 (ru) 5,5-дизамещённые-2-амино-4-тиазолидиноны и способ их получения, фармацевтическая композиция и способ лечения
BR112012010124A2 (pt) composto, uso de um animal composto, derivado de cromenona, e, método para o tratamento ou prevenção de um animal de sangue quente tendo tumores que são sensíveis á inibição das enzimas de pi 3-cinase
NO20063693L (no) Forbindelse og metode for anvendelse
NO20055129L (no) Fenylsubstituerte karboksylsyrer
MX2022015531A (es) Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo.
BR112022020814A2 (pt) Métodos para tratamento de síndrome de liberação de citocina
ATE513820T1 (de) Neue benzamidinderivate, verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
CN102526036A (zh) 一种含有丁苯酞和依达拉奉的复方注射液及制备方法
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
US20190343784A1 (en) Methods for using stabilized sulforaphene
Toussaint et al. Is serum phosphate a useful target in patients with chronic kidney disease and what is the role for dietary phosphate restriction?
AR112070A1 (es) Solución de infusión de levodopa
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
Kotake et al. Deprenyl decreases an endogenous parkinsonism-inducing compound, 1-benzyl-1, 2, 3, 4-tetrahydroisoquinoline in mice: in vivo and in vitro studies
JP2022110125A (ja) 炎症メディエーターのレベルを低減するための組成物及び方法
WO2023141334A3 (en) Pharmaceutical compositions of mycophenolic acid and/or betamethasone for the treatment of ocular disorders
BR112022019338A2 (pt) Tratamento preventivo de enxaqueca
BR112023005536A2 (pt) Medicamento, composição farmacêutica e método para a prevenção ou tratamento de dermatite atópica, e, uso de um composto